US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,363.33

-1.3197-0.10%

Number of Gainers:6

Number of Losers:14

Number of Flat:- -

PE:- -

High:1,380.29

Open:1,364.76

Low:1,361.70

Close:1,364.65

Loading ...

Gilead Sciences Announces First Quarter 2025 Financial Results

Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform

Health Rounds: Exposure to bacterial toxin may explain earlier age colon cancer rise

Pfizer (NYSE:PFE) Collaborates With Guardant Health on Oncology; Declares US$0.43 Dividend

Simply Wall St.

Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes

Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China

MT Newswires Live

Are Investors Undervaluing Pfizer (PFE) Right Now?

APT Electronics Announces Proposed Board and Supervisory Committee Elections

Moderna price target lowered to $26 from $32 at BofA

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (Easl) Congress 2025

THOMSON REUTERS

The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction

Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics

Equillium says FDA declines Breakthrough Therapy designation for itolizumab

Equillium Inc - Receives FDA Feedback on Itolizumab for Agvhd

THOMSON REUTERS

Equillium Inc - FDA Declines Breakthrough Therapy Designation for Itolizumab

THOMSON REUTERS

3 Healthcare Stocks Facing Headwinds

With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns

Simply Wall St.

Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1363.3257,"timestamp":1746020946147,"preClose":1364.6454,"halted":0,"volume":13778315,"delay":0,"changeRate":-0.000967,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-1.319702,"latestTime":"04-30 09:49:06 EDT","open":1364.7573,"high":1380.285,"low":1361.7031,"amount":604126006.114806,"amplitude":0.013617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.640146,"peRate":22.008402,"turnoverRate":0.000888,"increases":6,"decrements":14,"flats":0,"marketCap":1125795393421,"floatMarketCap":1106067307033.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1380.285,"amplitude":0.013617,"preClose":1364.6454,"low":1361.7031,"pbRate":"3.640146","latestPrice":1363.3257,"volume":13780227,"delay":0,"open":1364.7573,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1344.1606,"twentyDayClose":1377.6108,"sixtyDayClose":1350.7439,"secType":"PLATE","market":"US","turnoverRate":0.000888,"peRate":22.008402,"marketCap":1125890417645,"floatMarketCap":1106161006073.5,"timestamp":1746020947163,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":6,"down":14,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530186996","title":"Gilead Sciences Announces First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2530186996","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530186996?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:02","pubTimestamp":1745524920,"startTime":"0","endTime":"0","summary":"Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion. Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion. FOSTER CITY, Calif., April 24, 2025----Gilead Sciences, Inc.  announced today its first quarter 2025 results of operations.\"Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,\" said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. \"Our base business grew 4% year-over-year, primarily led by Biktarvy’s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer. With the upcoming June PDUFA date for lenacapavir for HIV prevention, and continued progress across our diverse pipeline, we look forward to building on our positive momentum throughout the year.\". As of March 31, 2025, Gilead had $7.9 billion of cash and cash equivalents compared to $10.0 billion as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-announces-first-quarter-200200808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1839511570.USD","IE00B3T34201.USD","BK4139","GILD","LU1585245621.USD","IE00B7SZLL34.SGD","LU2089984988.USD","LU2087621335.USD","IE00BSNM7G36.USD","BK4578","LU1066051498.USD","BK4566","BK4568","LU1066053197.SGD","BK4583","LU0889565916.HKD","BK4550","LU0234570918.USD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","IE0002270589.USD","LU0058720904.USD","BK4585","LU1430594728.SGD","BK4532","LU2468319806.SGD","IE00B19Z3581.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0109394709.USD","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2530964139","title":"Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2530964139","media":"Benzinga","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530964139?lang=en_us&edition=fundamental","pubTime":"2025-04-25 03:36","pubTimestamp":1745523394,"startTime":"0","endTime":"0","summary":"Guardant Health, Inc. on Thursday announced a strategic collaboration with Pfizer, Inc.  to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform.Under the multi-year collaboration agreement, Guardant and Pfizer aim to:. Utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies.Evaluate the clinical utility of  circulating tumor DNA  level as a surrogate endpoint to monitor therapy response and  related blood-based epigenomic analyses.Also Read: Medicare To Reimburse Guardant Health’s Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue. The collaboration will also allow Pfizer to access Guardant’s liquid biopsy tests in China for its global clinical trials, which include China cohorts.Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic  analysis to detect circulating tumor DNA , a marker of minimal residual dis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/guardant-health-pfizer-collaborate-develop-193634667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683348.USD","LU0122379950.USD","LU0234572021.USD","BK4535","GH","LU1066053197.SGD","LU1023059063.AUD","SG9999001176.SGD","SGXZ57979304.SGD","BK4213","LU1066051498.USD","CRC","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","LU0985481810.HKD","LU0225771236.USD","LU0456854461.SGD","BK4568","PFE","BK4581","LU1057294990.SGD","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","BK4196","BK4551","IE00BBT3K403.USD","LU0225284248.USD","BK4007","LU0289739699.SGD","LU0456855351.SGD","BK4588","LU0868494617.USD","IE00B19Z3B42.SGD","LU1883839398.USD","LU0266512127.USD","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","LU1894683264.USD","IE000M9KFDE8.USD","BK4534","BK4599"],"gpt_icon":1},{"id":"2530964899","title":"Health Rounds: Exposure to bacterial toxin may explain earlier age colon cancer rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2530964899","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530964899?lang=en_us&edition=fundamental","pubTime":"2025-04-25 03:08","pubTimestamp":1745521700,"startTime":"0","endTime":"0","summary":"Health Rounds: Exposure to bacterial toxin may explain earlier age colon cancer riseHealth Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidApril 24  - Hello Health Rounds Readers!","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nL1N3R00VS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU1066053197.SGD","BK4534","LU1066051498.USD","SG9999001176.USD","LU0122379950.USD","BK4581","LU1894683348.USD","LU1894683264.USD","LU0321505868.SGD","BK4592","IE00BBT3K403.USD","BK4550","SG9999002224.SGD","IE00B19Z3B42.SGD","BK4599","LU0306806265.USD","SG9999002232.USD","BK4585","SG9999013999.USD","LU0225284248.USD","LU0289739699.SGD","LU1057294990.SGD","SG9999003800.SGD","SG9999011175.SGD","BK4588","LU1023059063.AUD","LU0306807586.USD","LU0456855351.SGD","BK4533","IE00BLSP4452.SGD","LU0170899867.USD","LU0321505439.SGD","LU0234572021.USD","BK4007","LU0058720904.USD","LU0868494617.USD","LU0985481810.HKD","IE000M9KFDE8.USD","LU1883839398.USD","LU0225771236.USD","IE0002270589.USD","SGXZ57979304.SGD","BK4568"],"gpt_icon":1},{"id":"2530966405","title":"Pfizer (NYSE:PFE) Collaborates With Guardant Health on Oncology; Declares US$0.43 Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2530966405","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530966405?lang=en_us&edition=fundamental","pubTime":"2025-04-25 01:56","pubTimestamp":1745517389,"startTime":"0","endTime":"0","summary":"Pfizer recently made headlines with a strategic collaboration with Guardant Health, aimed at enhancing its oncology portfolio through advanced liquid biopsy technology. Simultaneously, the company maintained its strong commitment to shareholders by declaring a quarterly dividend. Pfizer's share price saw a modest increase of 1.59% over the past week, aligning with the broader market trend but slightly underperforming the 2.3% market surge. While these company-specific events underscored Pfizer’s strategic ambitions, they broadly contributed to the company’s standing in an optimistic market environment driven by earnings reports and broader economic sentiments.Be aware that Pfizer is showing 3 possible red flags in our investment analysis and 2 of those make us uncomfortable.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfizer-nyse-pfe-collaborates-guardant-175629624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","LU1894683348.USD","LU0306806265.USD","LU0170899867.USD","LU0456855351.SGD","LU0225771236.USD","LU0306807586.USD","LU0289739699.SGD","LU0321505868.SGD","LU0321505439.SGD","LU1883839398.USD","BK4568","BK4592","LU1057294990.SGD","LU1066051498.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU0234572021.USD","LU1023059063.AUD","SG9999003800.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU0985481810.HKD","BK4588","LU0058720904.USD","IE00BLSP4452.SGD","BK4007","NYSE","BK4599","BK4533","PFE","LU0122379950.USD","LU0868494617.USD","SG9999002224.SGD","LU0225284248.USD","IE00B19Z3B42.SGD","SG9999002232.USD","BK4581","SG9999013999.USD","BK4550","SG9999001176.USD","BK4534","SGXZ57979304.SGD","LU1066053197.SGD","IE00BBT3K403.USD","BK4585","SG9999011175.SGD"],"gpt_icon":1},{"id":"2530963931","title":"Leerink says Equillium’s itolizumab news ‘disappointing but not surprising’","url":"https://stock-news.laohu8.com/highlight/detail?id=2530963931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530963931?lang=en_us&edition=fundamental","pubTime":"2025-04-25 01:21","pubTimestamp":1745515287,"startTime":"0","endTime":"0","summary":"Leerink notes that Equillium (EQ) announced that the FDA declined to support an accelerated approval pathway for itolizumab in first-line treatment...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-says-equilliums-itolizumab-news-disappointing-but-not-surprising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-says-equilliums-itolizumab-news-disappointing-but-not-surprising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4568","EQ"],"gpt_icon":0},{"id":"2530957512","title":"GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2530957512","media":"NewMediaWire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530957512?lang=en_us&edition=fundamental","pubTime":"2025-04-25 00:00","pubTimestamp":1745510400,"startTime":"0","endTime":"0","summary":"GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations. ATLANTA, GA - April 24, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today recapped the successful presentation of new clinical data on its multi-antigen SARS-CoV-2 vaccine candidate, GEO-CM04S1, delivered at the 25th Annual World Vaccine Congress in Washington, D.C.The presentation, titled \"Phase 2b Study Results That Evaluated and Compared GeoVax's Multi-Antigen Vaccine Candidate  to an Approved Vaccine Against COVID-19,\" was given by Don J. Diamond, Ph.D. on April 24, 2025. It highlighted results across several Phase 1 and 2 clinical trials, including studies involving healthy volunteers as well as immunocompromised patients such as stem cell transplant recipients and those with chronic lymphocytic leukemia .GEO-CM04S1, based on the synthetic Modified Vaccinia Ankara  vector platf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-highlights-strong-clinical-results-160000967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4097","LU1894683348.USD","SG9999001176.SGD","BK4139","IE000M9KFDE8.USD","LU0985481810.HKD","LU0306806265.USD","LU0321505439.SGD","BK4539","LU1057294990.SGD","LU1066051498.USD","LU0225284248.USD","BK4599","LU0321505868.SGD","BK4568","SG9999013999.USD","LU0170899867.USD","BK4581","BK4551","IE00BBT3K403.USD","LU0122379950.USD","GOVXW","LU0234572021.USD","BK4535","BK4592","SG9999002232.USD","LU0868494617.USD","LU1883839398.USD","BK4533","SG9999003800.SGD","BK4232","BK4548","LU0058720904.USD","BK4585","LU2286300806.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","BNTX","GOVX","IE00BLSP4452.SGD","SG9999011175.SGD","LU1023059063.AUD","S","R","BK4560","LU0225771236.USD","BK4007","BK4588","SG9999002224.SGD","BK4022"],"gpt_icon":1},{"id":"2530895093","title":"EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes","url":"https://stock-news.laohu8.com/highlight/detail?id=2530895093","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530895093?lang=en_us&edition=fundamental","pubTime":"2025-04-24 23:39","pubTimestamp":1745509140,"startTime":"0","endTime":"0","summary":"Abbott’s ABT diversified business portfolio is well-positioned to drive continued momentum in 2025 amid foreign exchange headwinds. The stock carries a Zacks Rank #3 .Abbott’s Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. In a relatively short span, FreeStyle Libre has achieved global leadership among continuous glucose monitoring  systems for both Type 1 and Type 2 users.Foreign exchange is a major headwind for Abbott due to a considerable percentage of its revenues coming from outside the United States. The strengthening of the euro and some other developed market currencies has hampered the company’s performance in the international markets. In the first quarter of 2025, foreign exchange had an unfavorable year-over-year impact of 2.8% on sales.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/epd-growth-emerging-market-supports-153900859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0240877869.USD","LU0823416689.USD","LU1983299246.USD","SGXZ23171101.USD","IE00BJJMRZ35.SGD","BK4581","BK4590","IE0002141913.USD","LU2244417387.USD","IE00B2B36J28.USD","LU0353189680.USD","LU2764263039.SGD","BK4082","LU1721429741.USD","LU0187121727.USD","LU0266013472.USD","BK4585","LU0267386448.USD","MASI","BK4588","IE00B4R5TH58.HKD","LU0234572021.USD","LU1718418525.SGD","ABT","BK4566","IE0009355771.USD","LU2133065610.SGD","LU1989772840.SGD","LU2087625088.SGD","LU1691799644.USD","LU1989772923.USD","LU1989771016.USD","BK4533","BK4144","BK4568","BSX","LU2242649171.HKD","LU2324357040.USD","LU2265009873.SGD","LU2720916845.USD","LU1057294990.SGD","BK4561","LU0823417737.USD","EPD","LU0950375773.USD","LU1153585028.USD","LU2764263203.CNY","IE00BFTCPJ56.SGD","SG9999004303.SGD"],"gpt_icon":1},{"id":"2529222931","title":"Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529222931","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529222931?lang=en_us&edition=fundamental","pubTime":"2025-04-24 22:06","pubTimestamp":1745503584,"startTime":"0","endTime":"0","summary":"Guardant Health  and Pfizer,  disclosed a new, multi-year collaboration agreement on Thursday to support development and commercialization of Pfizer's oncology portfolio using the Guardant's Infinity liquid biopsy platform.Under the terms of the new partnership, the companies will evaluate the clinical use of circulating tumor DNA levels as a surrogate endpoint to monitor therapy response as well as related blood-based epigenomic analysis.The collaboration also will provide Pfizer with access to Guardant's liquid biopsy tests in China as the companies conduct clinical trials that include Chinese cohorts. Guardant previously formed a strategic partnership with Hong Kong-listed Adicon Holdings to offer Guardant tests to biopharmaceutical companies conducting clinical studies in China.Guardant shares recently were more than 1% higher in Thursday trading. Pfizer was narrowly higher this morning.Price: 46.30, Change: +0.66, Percent Change: +1.45","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000M9KFDE8.USD","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","GH","BK4568","BK4196","BK7095","BK4551","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","BK4535","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","PFE.AU","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2529955828","title":"Are Investors Undervaluing Pfizer (PFE) Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2529955828","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529955828?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:40","pubTimestamp":1745502012,"startTime":"0","endTime":"0","summary":"Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.One company to watch right now is Pfizer . PFE is currently sporting a Zacks Rank of #2  and an A for Value. The stock is trading with a P/E ratio of 7.54, which compares to its industry's average of 15.12. Over the past 52 weeks, PFE's Forward P/E has been as high as 12.11 and as low as 7.25, with a median of 10.22.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-undervaluing-pfizer-pfe-now-134012549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","BK4534","BK4211","IE0002270589.USD","IE00BLSP4452.SGD","LU1066053197.SGD","LU0225771236.USD","LU1057294990.SGD","LU0868494617.USD","LU0058720904.USD","LU0225284248.USD","BK4585","LU1066051498.USD","SG9999003800.SGD","BK4550","IE000M9KFDE8.USD","LU1883839398.USD","SG9999013999.USD","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999002232.USD","ISBC","LU0985481810.HKD","LU0306807586.USD","BK4599","IE00BLSP4239.USD","LU0306806265.USD","LU0122379950.USD","BK4007","LU0289739699.SGD","BK4588","LU0456855351.SGD","LU1894683348.USD","BK4592","LU1894683264.USD","SG9999001176.SGD","BK4533","SGXZ57979304.SGD","IE00B19Z3B42.SGD","BK4568","LU1023059063.AUD","LU0170899867.USD","PFE","SG9999001176.USD","LU0234572021.USD","SG9999002224.SGD","LU0321505868.SGD","BK4581","SG9999011175.SGD"],"gpt_icon":1},{"id":"2529627935","title":"APT Electronics Announces Proposed Board and Supervisory Committee Elections","url":"https://stock-news.laohu8.com/highlight/detail?id=2529627935","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529627935?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:37","pubTimestamp":1745501879,"startTime":"0","endTime":"0","summary":"APT Electronics Co., Ltd. Class H ( ($HK:2551) ) just unveiled an announcement. APT Electronics Co., Ltd. has announced the proposed election of it...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apt-electronics-announces-proposed-board-and-supervisory-committee-elections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apt-electronics-announces-proposed-board-and-supervisory-committee-elections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","APT","BK4086"],"gpt_icon":0},{"id":"2529935621","title":"Moderna price target lowered to $26 from $32 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529935621","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529935621?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:31","pubTimestamp":1745501515,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s revenue...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-price-target-lowered-to-26-from-32-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-price-target-lowered-to-26-from-32-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4533","BK4501","MRNA","BK4139","BK4548","BK4551","BK4585","BK4588","BK4532","BK4534"],"gpt_icon":0},{"id":"2529332759","title":"Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (Easl) Congress 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529332759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529332759?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:30","pubTimestamp":1745501400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nTUA1QVFKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","BK4535","BK4585","VIR"],"gpt_icon":0},{"id":"2529958648","title":"The Zacks Analyst Blog Highlights Coca-Cola, Abbott Laboratories, RTX, Investors Title and Armanino Foods of Distinction","url":"https://stock-news.laohu8.com/highlight/detail?id=2529958648","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529958648?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:22","pubTimestamp":1745500920,"startTime":"0","endTime":"0","summary":"Chicago, IL – April 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Coca-Cola Co. KO, Abbott Laboratories ABT, RTX Corp. RTX, Title Co. ITIC and Armanino Foods of Distinction, Inc. AMNF.Here are highlights from Wednesday’s Analyst Blog:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-coca-132200080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4212","LU0868494617.USD","LU0787776722.HKD","SG9999014575.USD","LU2237443465.HKD","LU0234572021.USD","LU1670710661.SGD","SG9999014559.SGD","LU0175139822.USD","LU0795875169.SGD","BK4568","IE00BDGV0183.EUR","BK4107","LU2112291526.USD","LU2125154935.USD","IE00BBT3K403.USD","RTX","LU1670710588.SGD","ITIC","SG9999011175.SGD","AMNF","LU0795875086.SGD","LU1162221912.USD","LU0950375773.USD","IE00BVYPNW00.USD","BK4177","SG9999002224.SGD","LU1929549753.HKD","LU2506952097.USD","ABT","LU2506951958.HKD","LU2347655156.SGD","LU2237957811.SGD","LU0640476718.USD","SG9999014567.USD","IE00BFTCPJ56.SGD","LU1003077747.HKD","LU0320765646.SGD","LU1280957306.USD","LU2237443622.USD","BK4592","BK4534","LU0098860793.USD","KO","LU1815333072.USD","LU0265550359.USD","SG9999002232.USD","LU0265550946.USD","LU1585245621.USD","BK4566"],"gpt_icon":1},{"id":"2529192956","title":"Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics","url":"https://stock-news.laohu8.com/highlight/detail?id=2529192956","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529192956?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:15","pubTimestamp":1745500520,"startTime":"0","endTime":"0","summary":"In its upcoming report, Astrazeneca  is predicted by Wall Street analysts to post quarterly earnings of $1.10 per share, reflecting an increase of 6.8% compared to the same period last year. Revenues are forecasted to be $13.68 billion, representing a year-over-year increase of 7.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.The collective assessment of analysts points to an estimated 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' of $154.45 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unveiling-astrazeneca-azn-q1-outlook-131520330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","LU0320765992.SGD","LU1829250122.USD","LU2417539215.USD","BK4568","BK4585","LU2456880835.USD","BK4588","LU2236285917.USD","LU2462157665.USD","LU0109394709.USD","BK4007","LU0889565916.HKD"],"gpt_icon":0},{"id":"2529381179","title":"Equillium says FDA declines Breakthrough Therapy designation for itolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2529381179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529381179?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:11","pubTimestamp":1745500317,"startTime":"0","endTime":"0","summary":"Equillium (EQ) announced that the company has received feedback from its Type D meeting with the FDA to discuss the regulatory pathway for accelera...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/equillium-says-fda-declines-breakthrough-therapy-designation-for-itolizumab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/equillium-says-fda-declines-breakthrough-therapy-designation-for-itolizumab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","EQ","BK4139"],"gpt_icon":0},{"id":"2529980168","title":"Equillium Inc - Receives FDA Feedback on Itolizumab for Agvhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980168","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529980168?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:06","pubTimestamp":1745499998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R236L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2529169980","title":"Equillium Inc - FDA Declines Breakthrough Therapy Designation for Itolizumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2529169980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529169980?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:06","pubTimestamp":1745499998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R236L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","EQ"],"gpt_icon":0},{"id":"2529958462","title":"3 Healthcare Stocks Facing Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2529958462","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529958462?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:02","pubTimestamp":1745499755,"startTime":"0","endTime":"0","summary":"From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.7%. This drop was worse than the S&P 500’s 7.5% loss.While some businesses have durable competitive advantages that enable them to grow consistently, the odds aren’t great for the ones we’re analyzing today. Keeping that in mind, here are three healthcare stocks that may face trouble.Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna  develops messenger RNA  medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.Sales tumbled by 59% annually over the last two years, showing market trends are working against its favor during this cycle. Free cash flow margin dropped by 369.1 percentage points over the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-healthcare-stocks-facing-headwinds-130235323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","LU0029864427.USD","BK4121","BK4532","BK4548","LU1267930573.SGD","LU1267930490.SGD","ZBH","BK4585","IE0034390439.USD","MRNA","BK4137","BK4551","HCSG","BK4139","BK4533","BK4534","BK4588","IE00B19Z3B42.SGD","BK4501","IE00B7SZLL34.SGD","IE00B19Z3581.USD","IE0002270589.USD","LU0708994859.HKD","LU0310799852.SGD","BK4566","IE00B19Z6F94.USD","LU0006061336.USD","IE00B64QTZ34.USD","LU0211327993.USD","LU0792757196.USD","TECH","LU1267930813.SGD","BK4568","LU0310800379.SGD","LU0211328371.USD","LU0889566641.SGD","BK4082","LU0128525929.USD"],"gpt_icon":0},{"id":"2529895584","title":"With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns","url":"https://stock-news.laohu8.com/highlight/detail?id=2529895584","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529895584?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:00","pubTimestamp":1745499612,"startTime":"0","endTime":"0","summary":"Institutions' substantial holdings in Pfizer implies that they have significant influence over the company's share price. 43% of the business is held by the top 25 shareholders. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.To get a sense of who is truly in control of Pfizer Inc. , it is important to understand the ownership structure of the business. The group holding the most number of shares in the company, around 67% to be precise, is institutions. That is, the group stands to benefit the most if the stock rises .Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait.Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/67-institutional-ownership-pfizer-inc-130012784.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0306807586.USD","BK4592","LU0058720904.USD","LU1894683348.USD","LU0122379950.USD","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","SG9999001176.SGD","SGXZ57979304.SGD","LU1066051498.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU0985481810.HKD","LU0225771236.USD","BK4568","PFE","BK4581","LU1057294990.SGD","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B19Z3581.USD","BK4007","LU0225284248.USD","LU0289739699.SGD","BK4588","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","NYSE","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","LU1894683264.USD","IE000M9KFDE8.USD","BK4534","BK4599"],"gpt_icon":1},{"id":"2529760934","title":"Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump","url":"https://stock-news.laohu8.com/highlight/detail?id=2529760934","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529760934?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:00","pubTimestamp":1745499600,"startTime":"0","endTime":"0","summary":"GALWAY, Ireland, April 24, 2025 /PRNewswire/ -- Medtronicplc , a global leader in healthcare technology, today announced it has submitted 510 applications to the U.S. Food and Drug Administration  seeking clearance for an interoperable pump. FDA clearance of this pump would pave the way for system integration with a continuous glucose monitoring  sensor based on Abbott's most advanced CGM platform.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and mor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/medtronic-advances-abbott-cgm-partnership-130000878.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medtronic-advances-abbott-cgm-partnership-130000878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0211326839.USD","LU1989763427.SGD","IE00BQXX3D17.EUR","LU1291159041.SGD","LU1116320737.USD","SGXZ23171101.USD","LU0976567544.SGD","IE00BQXX3F31.USD","LU1989764664.SGD","LU1057294990.SGD","BK4568","LU2237957811.SGD","LU2111349929.HKD","LU0170899867.USD","LU2112291526.USD","LU0265550359.USD","BK4585","ABT","LU2028103732.USD","LU2133065610.SGD","LU2023251221.USD","MDT","IE00BFXG1179.USD","BK4504","LU0070302665.USD","LU2089283258.USD","LU0162691827.USD","BK4592","IE00B2B36J28.USD","LU0234572021.USD","LU0266013472.USD","LU2468319806.SGD","LU0496365809.HKD","BK4588","LU1023059063.AUD","LU0265550946.USD","LU0868494617.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","SG9999004303.SGD","LU1914381329.SGD","LU0208291251.USD","IE0002141913.USD","IE00BJT1NW94.SGD","LU2089284900.SGD","LU0211331839.USD","LU1061106388.HKD","BK4581","LU1571399168.USD","IE00BQXX3C00.GBP"],"gpt_icon":0}],"pageSize":20,"totalPage":16,"pageCount":9,"totalSize":314,"code":"91000000","status":"200"}]}}